Motor deficits associated with changes in β-amyloid in Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 5, 2013, Pages 475-476

  Halliday, Glenda M ^a  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GAIT DISORDER; GENE MUTATION; HUMAN; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 84876154636     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304177     Document Type: Note

References (20)

1. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
2. 2 and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:537-43.
3. Aasly JO, Shi M, Sossi V, et al. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Neurology 2012;78:55-61.
4. Shi M, Furay AR, Sossi V, et al. DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging 2012;33:836e5-7.
5. Leverenz JB, Watson GS, Shofer J, et al. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17:61-4.
6. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-61.
7. Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24:2203-10.
8. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006;22:200-8. (Pubitemid 44310515)
9. Jokinen P, Scheinin N, Aalto S, et al. [(11) C]PIB-, [(18) F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010;16:666-70.
10. Halliday GM, Song YJ, Harding AJ. Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson's disease. J Neural Transm 2011;118:713-19.
11. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72:587-98.
12. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009:132(Pt 11):2947-57.
13. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011:134(Pt 5):1493-505.
14. Halliday G, Hely M, Reid W, et al. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115:409-15.
15. Halliday GM, Holton JL, Revesz T, et al. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011;122:187-204.
16. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010;1184:188-95.
17. Marras C, Lang A. Parkinson's disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry 2013;84:409-15.
18. Wylie SA, van den Wildenberg W, Ridderinkhof KR, et al. Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:1149-54.
19. Seichepine DR, Neargarder S, Miller IN, et al. Relation of Parkinson's disease subtypes to visual activities of daily living. J Int Neuropsychol Soc 2011;17:841-52.
20. Chung EJ, Kim EG, Kim MS, et al. Differences in myocardial sympathetic degeneration and the clinical features of the subtypes of Parkinson's disease. J Clin Neurosci 2011;18:922-5.